HealthDay News— Vaccination against human papillomavirus (HPV) in young males and hepatitis B in adults with diabetes mellitus is recommended by the Advisory Committee on Immunization Practices (ACIP) for infection control, according to two reports published in the Dec. 23 issue of the U.S. Centers for Disease Control and Prevention’s Morbidity & Mortality Weekly Report.
In the first report, Eileen F. Dunne, MD, of the CDC in Atlanta, and colleagues outline recommendations by the ACIP on the use of quadrivalent HPV vaccine (HPV4). In males aged 11 or 12 years of age, the committee recommends routine use of HPV4. In males aged 13 through 21 years, the committee recommends use of HPV4 in those who have not completed the three-dose vaccine series or have not been vaccinated previously. HPV4 may also be given to males age 22 through 26 years.
In the second report, Mark H. Sawyer, MD, of the University of California San Diego, and colleagues outline recommendations by the ACIP on the use of hepatitis B vaccination for adults with diabetes mellitus. For all previously unvaccinated adults aged 19 through 59 years with diabetes mellitus, the committee recommends vaccination against hepatitis B as quickly as possible after diabetes diagnosis (types 1 and 2). In unvaccinated adults ≥60 years of age with diabetes mellitus, the committee recommends hepatitis B vaccination at the discretion of the health care provider, as the data on the risk for hepatitis B in adults ≥60 years of age with diabetes mellitus is less robust than among those aged 19 through 59 years.
“Administration of the hepatitis B vaccine series should be completed as soon as feasible after diabetes is diagnosed. Available data do not confirm an advantage to any specific hepatitis B vaccine, dosage, or approved schedule for adults with diabetes. No serologic testing or additional hepatitis B vaccination is recommended for adults who received a complete series of hepatitis B vaccinations at any time in the past,” Sawyer and colleagues conclude.